IND for KL-A289 is Approved in China In August 2020, the IND for KL-A289 (anti-LAG-3 mAb) was approved by the NMPA to begin a Phase 1 clinical trial in China. LAG-3 has recen...
Looking for Partnerships to Combat COVID-19 KLUS Pharma is currently seeking co-development partnerships to conduct clinical trials on COVID-19 patients in countries and regions mos...
